Entheon Biomedical Corp.

Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses and optimizes the therapeutic potential of the DMT molecule. Entheon exists to invert the addiction-recovery ratio, turning the 'untreatable case' and 'lost cause' from the norm to the exception. We are committed to the legal development of regulated, safe & effective, psychedelic therapies, and in demonstrating their efficacy when administered in a scientifically-validated manner.

Recent News

  • Entheon Biomedical Corp. Announces Acquisition of HaluGen Life Sciences Inc.

    Vancouver, British Columbia--(Newsfile Corp. - January 14, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company") is pleased to announce that the Company completed its acquisition of HaluGen Life Sciences Inc. ("HaluGen"), a biotech company in the business of developing and commercializing a pre-screening test to identify genetic markers predictive of an individual's reaction to hallucinogenic drugs. The Company acquired 100% of the issued and outstanding common shares in the capital of HaluGen (the "HaluGen...

    2021-01-14 8:30 AM ET
  • Entheon Biomedical Engages Star Finance GmbH for Investor Relations

    Vancouver, British Columbia--(Newsfile Corp. - January 12, 2021) -  Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces that it has entered into a consulting agreement (the "Agreement") with Star Finance GmbH ("Star Finance"), a Swiss-based company, to provide European investor relations services. Star Finance has offices in Steinhausen, Switzerland, and Cologne, Germany. Star Finance is owned and operated by Michael Adams, who is a...

    2021-01-12 4:39 PM ET
  • Entheon Biomedical Engages World Renowned Media Personality DJ Skee, AKA Scott Keeney, as Media Advisor

    Vancouver, British Columbia--(Newsfile Corp. - January 11, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that it has engaged Mr. Scott Keeney, to serve as a media advisor. In his role, Mr. Keeney will work directly with the CEO of the Company, Timothy Ko, to develop multimedia campaigns and experiences specifically designed to define Entheon's role in the emerging psychedelic...

    2021-01-11 8:30 AM ET
  • Entheon Biomedical Announces Investment and Business Arrangement with Heading Health LLC

    Vancouver, British Columbia--(Newsfile Corp. - January 4, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is announcing a business arrangement with, and a strategic investment in, Heading Health, LLC ("Heading Health"), a psychiatric clinic platform focused on the administration of psychedelic-assisted therapy to treat mental health disorders.Entheon has participated in a Series A Preferred Stock Financing, investing $200,000 USD for a 5% stake in...

    2021-01-04 8:30 AM ET
  • Entheon Biomedical Closes Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - December 25, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company") announces that it has closed a non-brokered private placement financing for total gross proceeds of CAD $3,174,374.25 (the "Placement"). The majority of the Placement was subscribed for by strategic investors.The Company has allotted and issued 4,232,499 units (the "Units") at a price of CAD $0.75 per Unit. Each Unit is comprised of one common share and one-half of one...

    2020-12-25 8:30 AM ET
  • Entheon Biomedical Announces Private Placement

    Vancouver, British Columbia--(Newsfile Corp. - December 18, 2020) -  Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company") announces that it is proceeding with a fully allocated, non-brokered private placement financing of 4,266,997 Units (the "Units") at a price of CDN$0.75 per Unit for gross proceeds of CDN$3,200,247.75 (the "Placement"). This placement is fully subscribed by strategic investors and is expected to close on December 23rd. Each Unit will consist of one common share in the capital of...

    2020-12-18 5:16 PM ET
  • Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen Labs Inc. Completion of Initial DMT Research Drug Batch and Exercise of Warrants

    Vancouver, British Columbia--(Newsfile Corp. - December 9, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a drug-supply agreement (the "Agreement") with Psygen Labs Inc. ("Psygen"). Under the terms of the Agreement, Psygen will supply Entheon with non-GMP and GMP (good manufacturing practice) quality N,N-dimethyltryptamine drug substances ("DMT") for upcoming formulation, preclinical, clinical, and post-approval commercialization phases under the...

    2020-12-09 8:30 AM ET
  • Entheon Biomedical Announces Corporate Update Including Investment in Wonder Scientific

    Vancouver, British Columbia--(Newsfile Corp. - December 4, 2020) - Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1) ("Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, announces a strategic investment in Wonder Scientific Inc. ("Wonder Scientific").Wonder Scientific's team of University Researchers and Product Development experts create custom, naturally derived, active pharmaceutical ingredients (APIs) to supply the growing global clinical and commercial demand for psychedelics. Entheon's first strategic investment provides exposure in other verticals of the...

    2020-12-04 8:30 AM ET